GeoVax Q1 2026 net loss $5.3M; cash $1.3M; advances GEO-MVA Phase 3

GeoVax Labs, Inc.

Net loss of $5.3M for Q1 2026 vs $5.4M in Q1 2025; no revenue vs $1.6M prior (BARDA contract terminated).
Cash $1.3M at March 31, 2026, down from $3.1M at Dec 31, 2025.
Phase 3 immunobridging study for GEO-MVA (mpox/smallpox) planned under EMA-aligned expedited pathway; enrollment ~500.
Completed cGMP manufacturing and fill/finish; CRO selected for trial initiation.
Exclusive license from Emory for Gedeptin in combination with immune checkpoint inhibitors.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.